Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis
机构:[1]Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;中山大学肿瘤防治中心[2]Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[3]Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China临床科室内科中山大学肿瘤防治中心
Cisplatin and nedaplatin show significant antitumor activity and have been widely used for esophageal squamous cell carcinoma (ESCC). However, it is still unclear whether the efficacy and safety of nedaplatin-based regimens are comparable to those of cisplatin-based regimens in patients with metastatic/recurrent or advanced ESCC. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy and safety of these two regimens for the treatment of metastatic/recurrent and advanced ESCC. We systematically searched Pubmed, Web of Science, and the Cochrane Database, as well as abstracts presented at conferences (all up to January 2015), for randomized-controlled and nonrandomized clinical trials that compared cisplatin-based and nedaplatin-based regimens in patients with metastatic/recurrent or advanced ESCC. Data were extracted from the original studies by two independent reviewers. This meta-analysis was performed usingReviewManager (RevMan) Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) software. Ten eligible trials, including 598 patients diagnosed with metastatic/recurrent or advanced ESCC, were included in our analysis. Our results demonstrated that the nedaplatin-based regimens were comparable to the cisplatin-based regimens in terms of overall survival (OS) (hazard ratio, HR: 1.22, 95% confidence interval, CI: 0.86-1.74, p=0.26) and overall response rate (ORR) (risk ratio, RR: 0.92, 95% CI: 0.77-1.10, p=0.37) and generated fewer grade 3 and 4 side effects including nausea (RR: 3.41, 95% CI: 1.67-6.96, p<0.001) and vomiting (RR: 3.62, 95% CI: 1.77-7.40, p<0.001) and fewer grade 1 and 2 adverse events including nausea (RR: 1.54, 95% CI: 1.23-1.93, p<0.001), vomiting (RR: 1.76, 95% CI: 1.76-2.30, p<0.001), peripheral neuropathy (RR: 1.75, 95% CI: 1.08-2.84, p=0.02) and renal dysfunction (creatinine) (RR: 3.28, 95% CI: 1.37-7.84, p=0.008). This systematic review and meta-analysis indicated that the efficacy of nedaplatin-based regimens was comparable to that of cisplatin-based regimens for patients with metastatic/recurrent or advanced ESCC, and that nedaplatin-based regimens were associated with less toxicity and better tolerability. However, this study was a meta-analysis of previously released data; therefore, there is a potential publication bias and heterogeneity among the included trials. Future, well-designed RCTs with large cohorts are warranted.
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|3 区医学
小类|4 区胃肠肝病学
最新[2023]版:
大类|3 区医学
小类|4 区胃肠肝病学
第一作者:
第一作者机构:[1]Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;[2]Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;[3]Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
通讯作者:
通讯机构:[1]Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;[2]Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China;[3]Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
Zhang Fei,Wang Yun,Wang Zhi-Qiang,et al.Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis[J].DISEASES OF THE ESOPHAGUS.2017,30(2):-.doi:10.1111/dote.12490.
APA:
Zhang, Fei,Wang, Yun,Wang, Zhi-Qiang,Sun, Peng,Wang, De-Shen...&Li, Yu-Hong.(2017).Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.DISEASES OF THE ESOPHAGUS,30,(2)
MLA:
Zhang, Fei,et al."Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis".DISEASES OF THE ESOPHAGUS 30..2(2017):-